BR112014024275A2 - "aptamers for pdgf and vegf, aptamer constructs and their uses" - Google Patents

"aptamers for pdgf and vegf, aptamer constructs and their uses"

Info

Publication number
BR112014024275A2
BR112014024275A2 BR112014024275A BR112014024275A BR112014024275A2 BR 112014024275 A2 BR112014024275 A2 BR 112014024275A2 BR 112014024275 A BR112014024275 A BR 112014024275A BR 112014024275 A BR112014024275 A BR 112014024275A BR 112014024275 A2 BR112014024275 A2 BR 112014024275A2
Authority
BR
Brazil
Prior art keywords
aptamers
aptamer
pdgf
vegf
constructs
Prior art date
Application number
BR112014024275A
Other languages
Portuguese (pt)
Other versions
BR112014024275B1 (en
Inventor
D Gelinas Amy
Zhang Chi
W Drolet Daniel
C Rohloff John
Janjic Nebojsa
M Waugh Sheela
C Jarvis Thale
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Priority claimed from PCT/US2013/034493 external-priority patent/WO2013149086A1/en
Publication of BR112014024275A2 publication Critical patent/BR112014024275A2/en
Publication of BR112014024275B1 publication Critical patent/BR112014024275B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

abstract aptamers that bind pdgf and aptamers that bind vegf are provided. in addition, aptamer constructs comprising a pdgf aptamer and a vegf aptamer are provided. pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs tradução do resumo resumo "aptâmeros para pdgf e vegf e seu uso no tratamento de condições mediadas por pdgf e vegf" são fornecidos aptâmeros que ligam pdgf e aptâmeros que ligam vegf. além disso, construtos de aptâmero compreendendo um aptâmero de pdgf e um aptâmero de vegf são fornecidos. composições farmacêuticas compreendendo os aptâmeros e construtos de aptâmero são fornecidas, bem como métodos de tratamento de condições usando os aptâmeros e construtos de aptâmero.abstract aptamers that bind pdgf and aptamers that bind vegf are provided. in addition, aptamer constructs including a pdgf aptamer and a vegf aptamer are provided. pharmaceutical compositions including the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs binding pdgf and vegf binding aptamers. In addition, aptamer constructs comprising a pdgf aptamer and a vegf aptamer are provided. Pharmaceutical compositions comprising aptamers and aptamer constructs are provided, as well as methods of treating conditions using aptamers and aptamer constructs.

BR112014024275-5A 2012-03-28 2013-03-28 Aptamers for pdf and vegf, their use and aptamer construct BR112014024275B1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261616884P 2012-03-28 2012-03-28
US61/616,884 2012-03-28
US201261648394P 2012-05-17 2012-05-17
US61/648,394 2012-05-17
US201261719354P 2012-10-26 2012-10-26
US61/719,354 2012-10-26
US201261722099P 2012-11-02 2012-11-02
US61/722,099 2012-11-02
PCT/US2013/034493 WO2013149086A1 (en) 2012-03-28 2013-03-28 Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions

Publications (2)

Publication Number Publication Date
BR112014024275A2 true BR112014024275A2 (en) 2017-07-25
BR112014024275B1 BR112014024275B1 (en) 2022-02-22

Family

ID=80741908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014024275-5A BR112014024275B1 (en) 2012-03-28 2013-03-28 Aptamers for pdf and vegf, their use and aptamer construct

Country Status (1)

Country Link
BR (1) BR112014024275B1 (en)

Also Published As

Publication number Publication date
BR112014024275B1 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
CL2015000092A1 (en) Chirally controlled oligonucleotides, composition comprising them; Method of elaboration: and use to treat cancer.
CL2017000888A1 (en) Antibody molecules that bind to pd-l1 and uses thereof
ECSP17041865A (en) ANTI-CD47 ANTIBODIES AND USES OF THEM
BR112015022191A2 (en) heteroaryl compounds, their use and composition comprising them
CL2015001157A1 (en) Compositions and methods to treat proteinopathies.
AR090903A1 (en) ANTI-PMEL ANTIBODIES AND IMMUNOCADES17
CO7240361A2 (en) Compositions of arni de serpinc1 and methods of use thereof
AR091024A1 (en) ANTIBODIES ABLE TO JOIN THE COAGULATION XI FACTOR AND / OR ITS ACTIVATED FORM, XIA FACTOR, AND ITS USES
CL2014003136A1 (en) New diazaespirocicloalcanos and azaespirocicloalcanos; Pharmaceutical composition that contains them and uses.
BR112015004817A2 (en) bioconjugates comprising modified antigens and their uses
BR112015014063A2 (en) human anti-b7-h4 antibodies and their uses.
AR091959A1 (en) SYNTHETIC SUSTAINABLE AGENTS AND MONODISPERSE SUSTAINABLE AGENTS AND METHODS FOR THE ELABORATION OF THE SAME
UY35407A (en) ? FUSION PROTEINS UNDERSTANDING UNION PDGF and VEGF PORTIONS AND METHODS FOR USE ?.
CO6650338A2 (en) Modified TB Antigens
CL2014001291A1 (en) Double-stranded iarn agents; compositions and methods of use thereof to treat diseases associated with transthyretin (ttr).
BR112012020558A2 (en) androgen receptor modulators and their uses
AR092662A1 (en) ANTI-DDR1 ANTIBODIES
BR112016000779A2 (en) autotaxin inhibitors comprising heteroaromatic ring benzylamide cycle nucleus, their pharmaceutical uses, composition and combination
BR112014026990A2 (en) antibody, nucleic acid, vectors, host cell, pharmaceutical composition, use of an antibody and method for treating a patient in need of therapy.
AR091316A1 (en) HUMAN UNION MOLECULES THAT CAN BE JOINED AND NEUTRALIZED THE INFLUENZA B VIRUSES AND THEIR USES
AR090465A1 (en) SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFARMACO
EA201492289A1 (en) COMPOSITIONS CONTAINING AN APTAMER AGAINST PDGF AND ANTAGONIST VEGF
BR112012018021A2 (en) anticoagulant antidotes.
CO2018012513A2 (en) Antibodies
BR112014026740A8 (en) antibody, composition, method of providing an antibody with enhanced adcc, and, use of an antibody

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12Q 1/68

Ipc: C12N 15/115 (2010.01), A61K 31/7115 (2006.01), A61

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/2013, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: SOMALOGIC OPERATING CO., INC. (US)